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ABSTRACT
Background Carcinomas of the Vaterian system are rare
and presumably arise from pre-existing adenomas.
According to the cancer stem cell (CSC) hypothesis, only
a small subset of tumor cells has the ability to initiate
and develop tumor growth. In colorectal cancer, CD44,
CD133, CD166 and EpCAM have been proposed to
represent CSC marker proteins and their expression has
been shown to correlate with patient survival.
Aims To evaluate a potential role of these CSC proteins
in tumors of the ampulla of Vater, we investigated their
expression in 175 carcinoma, 111 adenoma and 152
normal mucosa specimens arranged in a Tissue
Microarray format.
Materials and methods Membranous
immunoreactivity for each protein marker was scored
semi-quantitatively by evaluating the number of positive
tumor cells over the total number of tumor cells. Median
protein expression levels were used as cut-off scores to
define protein marker positivity. Clinical data including
survival time were obtained by retrospective analysis of
medical records, tumor registries or direct contact.
Results The expression of all evaluated marker proteins
differed significantly between normal mucosa, adenoma
and carcinoma samples. In all markers, we found
a tendency towards more constant expression from
normal to neoplastic tissue. EpCAM expression was
significantly correlated with better patient survival. The
increased expression of CD44s, CD166 and CD133 from
normal mucosa samples to adenoma and carcinoma was
linked to tumor progression. However, there was no
statistically significant correlation with survival.
Conclusion Our findings indicate, that in ampullary
carcinomas, loss of expression of EpCAM may be linked
to a more aggressive tumor phenotype.
INTRODUCTION
The ampulla of Vater combines the terminal and
common segment of the bile and pancreatic duct
before they enter the duodenum.1 Carcinomas
originating from this complex anatomical unit are
uncommon and have an incidence of approximately
four to six cases per million population.2 3 Carci-
nomas of the papilla of Vater, deﬁned as junction of
the biliary, and pancreatic ducts within the
duodenum account for 6%e20% of all peripancre-
atic tumours4 and represent 10%e50% of all
cancers resected by pancreaticoduodenectomy.5
They can be sited in the ampulloduodenal part of
the papilla of Vater, which is lined by intestinal
mucosa. They also can develop in deeper parts of
the ampulla, which are lined by pancreaticobiliary
duct mucosa. Clinically, tumours of the ampulla of
Vater are rapidly detected due to biliary outﬂow
obstruction.6 7 Early symptoms as well as differ-
ences in tumour biology are held responsible for
their favourable clinical outcome (median survival
30e50 months, 5-year survival rate 21%e64%).8 9
Histologically, intestinal, pancreaticobiliary, intes-
tinal-mucinous, invasive papillary and poorly
differentiated subtypes can be distinguished.10 The
subtypes differ in several clinical and histological
aspects including cell type-speciﬁc markers, onco-
gene expression, modes of tumour spread as well as
extent and interaction with the extracellular
matrix.11 Most authors agree that local spread of
the tumour (T stage) is the only signiﬁcant and
independent prognostic factor for this cancer,
whereas the predictive value of tumour grade and
lymph node metastases is still debated.12 13 More
recent research data suggest that the prognosis of
ampullary cancer may be related to the histological
differentiation in intestinal or pancreatobiliary
types.14 In the last years, several molecular markers
have been proposed as additional prognostic
factors. However, most of these studies have
yielded conﬂicting results and have not been still
validated by other reports.15e19 Several sources of
discrepancy between different reports have been
acknowledged mainly due to non-standardised
assays often performed on underpowered patient
samples that are too small to enable meaningful
conclusions to be drawn. Therefore, there is
undoubtedly a need for additional prognostic
markers for such neoplasia. Recent ﬁndings support
the concept that cells with the properties of stem
cells are integral to the development and perpetu-
ation of several forms of human cancer.20 21 Cancer
stem cells (CSCs) have low replicative ability,
multipotency and resistance to apoptosis and are
responsible for tumour development.22 In the
different types of digestive tumours, different sets
of markers have emerged as the most useful for the
identiﬁcation of CSC. In particular, in intestinal as
well as in pancreatic cancer, some markers
including CD44, EpCAM, CD166 and CD133 have
been indicated as possible CSCs markers. Further-
more, in colorectal cancer, we have shown that
their expression inversely correlated with patient
survival.23 However, conﬂicting results have been
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reported about the role of some putative CSC markers in
gastrointestinal tract tumours. In particular, contradictory
ﬁndings have been reported about the association of CD44, in
particular of its v6 splicing variant, and tumour
progression.24e26 Furthermore, while CD133 molecule was
initially identiﬁed as a reliable CSC marker in human colorectal
cancers,27 28 a subsequent study has shown that in both mouse
and human colorectal cancers, CD133 expression is not
restricted to rare cell subsets, but it is detectable in a large
majority of tumour cells, irrespective of their tumourigenicity.29
Because of the lacking studies dealing with CSC markers in
ampullary tumours, the aim of this study was to elucidate the
expression and the prognostic role of CD133, CD166, CD44s,
EpCAM expression in ampullary tumours by using a tissue
microarray (TMA) including 175 carcinoma, 111 adenoma and
152 normal mucosa specimens of the papilla of Vater.
MATERIAL AND METHODS
Ethics
The study has been approved by the institutional review board
of the Department of Pathology, University of Basel,
Switzerland. All the analyses were performed according to the
ethical standards required by each local ethic committee.
Patients’ characteristics and tissue samples
Patients’ characteristics have been previously described by our
study group.30 31 Brieﬂy, the ﬁles of the Institute of Pathology,
University Hospital Basel (Switzerland), the Institute of
Pathology, University of Regensburg (Germany), the Institute of
Pathology Nuernberg and the Anatomic Pathology Unit,
Department of Human Morphology, University of Insubria,
Varese (Italy), were searched for adenomas or carcinomas of the
ampulla of Vater over the period from 1985 to 2005. In total, 175
carcinoma, 111 adenoma and 152 normal mucosa samples were
retrieved. Sufﬁcient parafﬁn-embedded tissue for TMA
construction was available in all cases. The male-to-female ratio
was 3:2; mean age at diagnosis was 63 years (range
15e81 years). To our knowledge, no case was associated with
Familial adenomatous polyposis (FAP).
TMA construction
TMAs were constructed from formalin-ﬁxed and parafﬁn-
embedded specimens using a custom-built instrument (Beecher
Instruments, Silver Spring, Maryland, USA) as previously
described.30 31 Brieﬂy, H&E-stained sections were obtained from
each selected primary block (donor block) to deﬁne representa-
tive tissue regions. Core biopsies (0.6 mm cylinders) were taken
from the selected tissue regions and then transferred to
a parafﬁn recipient block. The resulting TMAwas cut into 4 mm
sections, which were used for immunohistochemistry. The
number of punches per patient ranged from one to three for
both normal tissue and carcinoma and from one to ﬁve for
adenomas. If more than one punches was obtained, the addi-
tional punches were taken from different representative blocks.
Histology and immunophenotyping
All tumours were classiﬁed according to the guidelines of the
Armed Forces Institute of Pathology using only H&E stains.10
Mild dysplasia was designated as low-grade dysplasia, whereas
moderate and severe dysplasia was considered as high-grade
dysplasia. Carcinomas histologically indistinguishable from
colorectal carcinomas were classiﬁed as intestinal types, whereas
carcinomas showing a dense desmoplastic stroma surrounding
small glands or solid nests of tumour cells were referred to as the
pancreaticobiliary subtype. Invasive papillary carcinomas typi-
cally formed papillary and micropapillary structures in their
invasive component and poorly differentiated adenocarcinomas
lacked histologic features of glandular or other differentiation.
Additionally, an intestinal-mucinous subtype, characterised by
any mucinous differentiation, was deﬁned.
For immunohistochemistry, sections were pre-treated with
CC1 (Ventana Medical Systems, Tucson, Arizona, USA) and
incubated with primary antibodies against CD133, CD44s,
CD166 and EpCAM (table 1). Staining procedures were
performed on a Benchmark immunohistochemistry staining
system (Ventana Medical Systems) using iVIEW-DAB as
chromogen.
Membranous immunoreactivity for each protein marker was
scored semiquantitatively by evaluating the number of positive
tumour cells over the total number of tumour cells. Scores were
assigned using 5% intervals and ranged from 0% to 100%. All
tissues were scored by an experienced pathologist (LT), blinded
to clinicopathological information. To deﬁne interobserver
agreement, all samples were examined independently by
a second pathologist (DB).
Statistical analysis
Statistical correlations between categorical variables were tested
using a c2 or Fisher exact test, where appropriate. Differences in
patient survival were demonstrated using the KaplaneMeier
method and analysed using the log-rank test in univariate
analysis. All tests were two sided. p Values <0.05 were consid-
ered statistically signiﬁcant. Cut-off scores were selected by
evaluating the receiver operating characteristic curves for each
protein marker and the end-point survival. The point on the
curve with the shortest distance to the coordinate (0, 1) was
selected as the threshold value to classify cases as ‘positive/
overexpressing’ or ‘negative/loss’.32 Analysis was performed
using SAS V.9.1 (SAS Institute).
RESULTS
Patients’ characteristics and tissue samples
Overall, 175 carcinoma, 111 adenoma and 152 normal mucosa
samples were retrieved. In patients with carcinomas, we found
19 pT1 (11%), 59 pT2 (34%), 63 pT3 (36%) and 13 pT4 (7%)
tumours as well as 17 G1 (10%), 82 G2 (47%) and 55 G3 (31%)
cases (no data concerning T stage and grading in 21 samples).
Seventy-three (42%) carcinoma patients were node positive and
two (1%) had haematogenous metastases at initial diagnosis.
Full clinical data including survival time were available in 133
patients with ampullary carcinoma (76%). Patients were studied
up to 164 months after operation. Median follow-up time was
36 months.
The histological classiﬁcation of 175 ampullary carcinomas
identiﬁed 85 intestinal types, 42 pancreaticobiliary types, 23
poorly differentiated adenocarcinomas, 16 intestinal-mucinous
types and nine invasive papillary types.
Table 1 Primary antibodies against CD133, CD44, CD166 and EpCAM
Antibody Dilution/detection Pretreatment
CD44 (Dako, DF1485) 1:50/BOND BOND ER2
CD133 (cell signalling, C24B9) 1:100/BOND Steamer 1208C, pH8
CD166 (Novocastra, MOG/07) 1:200/BOND BOND ER2
EpCAM (Novocastra, VU-1D9) 1:200/BOND BOND ER2
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Histological grading was evaluable in 76 of 111 (68%)
adenomas and disclosed low-grade dysplasia in 57 of 76 (75%)
and high-grade dysplasia in 19 of 76 (25%) cases. All adenomas
demonstrated tubular or tubulovillous architecture. Seventy-
eight of 111 (70%) adenoma samples were derived from patients
with coexisting carcinoma.
Immunophenotyping
Tissue samples of ampullary carcinoma patients expressing
CD44, CD133, CD166 and EpCAM are shown in ﬁgure 1.
Moreover, in table 2, the distribution of the different biomarkers
across different diagnostic categories is shown.
The expression of all marker proteins differed signiﬁcantly
between carcinoma, adenoma and normal mucosa samples
(table 3).
We have also evaluated the positivity in the two principal
histologic types (intestinal type vs pancreatobiliary type).
EpCAM was signiﬁcantly more expressed in intestinal type
(table 4).
We have tried also to evaluate if there is some difference
between adenomas without coexisting carcinoma and adenomas
without coexisting carcinomas. Only CD44 was signiﬁcantly
more expressed in adenomas with coexisting carcinomas
(p¼0.043).
No difference was found between low-grade and high-grade
adenomas (data not shown).
Survival
Five-year survival (95% CI) was 45.2 (34 to 56) in EpCAM-
positive versus 28.2 (11 to 48) in EpCAM-negative patients
(p<0.05). EpCAM was not an independent prognostic factor
after adjusting for pT and pN stages. Survival curves of
both patient groups using the KaplaneMeier method are
demonstrated in ﬁgure 2.
DISCUSSION
Tumours of the papilla of Vater are a relatively rare neoplastic
entity that came into focus in recent years. Signiﬁcant overlap
exists in phenotypic and molecular characteristics between
ampullary and colorectal carcinomas. As in colorectal cancer, the
development of ampullary carcinoma from adenomas as
precancerous lesions has been well documented, and studies
investigating molecular alterations associated with the proposed
adenomaecarcinoma sequence have been also performed,
including our group.33 However, still missing is a comprehensive
analysis of the expression of putative CSC markers in very large
groups of patients, amenable to detailed statistical analysis.
Moreover, the prognostic signiﬁcance of the co-expression of
multiple CSC markers within the same tumour has not been
evaluated so far.
This is the ﬁrst systematic study assessing the prognostic
value of four CSC markers, namely EpCAM, CD44, CD133 and
CD166, in a large series of patients with ampullary tumours.
Figure 1 Immunophenotyping in
tissue samples from patients with
ampullary carcinoma (4003). (A) CD44.
(B and C) CD133. (D and E) CD166. (F)
EpCAM.
Table 2 Distribution of biomarkers between different diagnostic categories
Number of cases within each expression category
Sum0% 1%e5% 6%e20% 21%e40% 41%e60% 61%e80% 81%e100%
Normal
CD133 9 63 30 0 1 1 0 104
CD44 67 20 8 7 3 6 4 115
CD166 81 5 6 3 6 1 13 115
EpCAM 7 1 0 0 2 2 89 101
Adenoma
CD133 10 61 14 0 0 0 0 85
CD44 25 13 17 5 3 14 12 89
CD166 58 9 5 1 4 3 6 86
EpCAM 0 0 0 1 2 1 89 93
Cancer
CD133 16 83 45 6 1 0 0 151
CD44 38 15 27 19 9 18 18 144
CD166 84 19 14 9 5 7 10 148
EpCAM 2 0 1 1 3 3 136 146
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The overexpression of EpCAM was signiﬁcantly correlated with
better survival time. The increasing expression of CD44, CD166
and CD133 from normal mucosa samples to adenoma and
carcinoma was linked to tumour progression. However, there
was no statistically signiﬁcant correlation with survival.
EpCAM is a glycosylated, 30e40 kDA type I membrane
protein, which is expressed in a variety of human epithelial
tissue cancers, as well as in progenitor and stem cells. It is
composed of an extracellular domain with epidermal growth
factor and thyroglobulin repeat-like domains, a single trans-
membrane domain and a short 26 amino acid intracellular
domain called EpICD. In normal cells, EpCAM is predominantly
located in intercellular spaces, where epithelial cells form very
tight junctions. Therefore, on normal epithelia, it is sequestered
and may be much less accessible to antibodies than in cancer
tissue, where it is homogeneously distributed on the cell
surface. Furthermore, EpCAM is part of the signature of cancer-
propagating cells in numerous solid tumours as well as in normal
progenitor and stem cells.34
EpCAM was one of the ﬁrst tumour-associated antigens
identiﬁed in the late 1970s. Systematic analysis of EpCAM
expression for intensity and frequency showed that EpCAM
is expressed on essentially all human adenocarcinoma, on
certain squamous cell carcinoma, on retinoblastoma and on
hepatocellular carcinoma.35
Importantly, EpCAM is part of the signature of cancer-
propagating cells in numerous solid tumours and of normal
progenitor and stem cells.34 The controversial biological role of
EpCAM has recently been discussed by van der Gun et al.36 It is
of interest that EpCAM overexpression has been associated
with both decreased and increased survival time. EpCAM exerts
different effects on cell adhesion, either promoting or
preventing metastasis.36 The correlation of EpCAM expression
and poor survival has been described in several tumour types,
including invasive breast cancer,37 urothelial carcinoma of the
bladder,38 gallbladder carcinoma39 40 and squamous cell carci-
noma of the oesophagus.41 In different tumours, studies on
EpCAM-directed immunotherapeutic therapies are currently in
clinical development. Therapeutic trials of monoclonal anti-
bodies directed against EpCAM have shown that they may
induce antibody-based cellular cytotoxicity by adhering
to cytokines such as interleukin 2 or complement-based
cytotoxicity by activating T cytotoxic cells.42 43
Previous studies have yielded conﬂicting results regarding
EpCAM expression and survival in ampullary carcinoma. By
Scheunemann et al,44 EpCAM expression has been associated
with poorer survival in tumours of the papilla of Vater. This
study, however, was mainly focused on the frequency and
prognostic impact of minimal tumour cell spread in lymph
nodes classiﬁed as ‘tumour free’ in routine histopathologic
evaluation, and EpCAM expression in primary tumours was not
analysed.
More recently, Fong et al45 were unable to prove a prognostic
value of EpCAM overexpression in pancreatic and ampullary
carcinoma. In contrast, in our study, we showed that decreased
EpCAM membranous expression signiﬁcantly correlated with
biological features of aggressive tumour behaviour. Our study
therefore suggests that diminished EpCAM expression is related
to tumour invasiveness and progression and it is linked to a more
aggressive tumour phenotype. This could also be conﬁrmed by
the more frequent expression of EpCAM in intestinal-type than
in pancreatobiliary-type tumours. Intestinal-type tumours are in
fact associated with a better prognosis.14
Several reasons for the discrepancies between our results and
previous studies can be hypothesised including differences in
sample size (power for detecting prognostic differences), meth-
odology (TMA vs whole tissue sections), different clones of
antibody and, most importantly, the choice of cut-off scores for
the deﬁnition of positive staining or staining intensity.
EpCAM is intensely used as a therapeutic target for antibody-
based approaches. Future development of EpCAM-directed
therapeutics may proﬁt from newly identiﬁed functions of
EpCAM as mitogenic signal transducer in various ways. An
important insight is that EpCAM is apparently needed to
maintain distinct cancer cell attributes46 and, potentially, the
CSC phenotype as well. This function can reduce the risk of
immune escape by loss of EpCAM target expression from cancer
cells. EpCAM-directed therapies may be selective for those
cancer cells with the strongest negative impact on prognosis and
for cancer-propagating subsets of malignant cells.
Discrepant results have also been reported regarding the
effect of CD44 gene or protein and its splice variants on survival
in tumour patients and it is an important receptor that binds
hyaluronan (HA). CD44 has previously been considered to be
a marker of tumour invasiveness and metastasis. Only recently,
it has been described as putative colorectal CSC marker.
Table 3 Expression of all evaluated marker proteins in normal mucosa,
adenoma and carcinoma samples
Normal Adenoma Carcinoma p Value
CD44+ (>5%) 29/118 (24.6%) 52/90 (57.8%) 91/145 (62.8%) <0.001
CD133+ (>5%) 30/104 (28.9%) 11/74 (12.9%) 44/151 (29.1%) 0.012
CD166+ (>0%) 34/120 (28.3%) 28/87 (32.2%) 64/151 (42.4%) 0.044
EpCAM +(100%) 89/104 (85.6%) 88/93 (94.6%) 115/145 (79.3%) 0.005
Table 4 Expression of evaluated markers in the two principal histologic
subtypes of ampullary carcinoma
Intestinal Pancreatobiliary p Value
CD44+ (>5%) 82/99 (82.8%) 33/41 (80.5%) 0.805
CD133+ (>5%) 27/88 (30.7%) 12/40 (30.0%) 0.938
CD166+ (>0%) 73/97 (76.8%) 32/44 (72.7%) 0.672
EpCAM+ (100%) 68/75 (90.7%) 25/33 (75.8%) 0.039
The bold value means that EpCAM overexpression is statistically significant.
Figure 2 Survival of patients with EpCAM-positive and -negative
ampullary carcinoma using the KaplaneMeier method.
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However, CD44 does not seem to belong to the group of genes,
such as OCT4 and NANOG, that are central for maintaining
stem cell characteristics. Nonetheless, two connections
between CD44 and genes that regulate stem cell characteristics
have been described. First, CD44 is a target of the WNT
pathway. Loss of adenomatous polyposis coli (APC) function
leads to the constitutive activation of b catenin, a constituent
of the WNTsignalling pathway. CD44s and CD44v6 expression
is restricted to the intestinal crypts in non-transformed tissue,
but both CD44 isoforms are strongly overexpressed in
dysplastic crypts and adenomas in humans and mice with
mutant APC.47 Second, HAeCD44 binding promotes protein
kinase C (PKC) activation and this increases NANOG phos-
phorylation and translocation to the nucleus. Here, it associates
with Drosha and an RNA helicase, p68, leading to the tran-
scription of the oncogenic microRNA (miRNA) miR-21 and
a reduction in the expression of the tumour suppressor
programmed cell death 4. These events initiate the upregulation
of the inhibitor of apoptosis (IAP) proteins and multidrug
resistant protein 1 (MDR1). CD44, in turn, associates with and
stabilises MDR1 expression.48 This could be one mechanism
through which CD44 contributes to stem cell resistance to
chemotherapy, as MDR1 exports several drugs from cells.
In several gastrointestinal tumours, including colorectal
cancer,23 stromal49 as well as neuroendocrine tumours,50 loss of
CD44 expression has been associated with disease progression
and reduced survival. In our study, CD44 expression was
more frequently associated with adenomas with coexisting
carcinomas.
Our study is also the ﬁrst to evaluate the prognostic impact of
CD166 in ampullary carcinoma. We found an increasing
expression of CD166 from normal tissue to carcinoma,
suggesting that the increased expression of this marker might be
linked to tumour progression. Our data are supported by
a recent study in colorectal cancer patients, where a similar
increasing expression of CD166 from normal to neoplastic tissue
has been described by Weichert et al.51
We speculate that our ﬁndings of decreased rather than
increased expression of membranous EpCAM expression and its
association with features of tumour progression are mainly
a consequence of its cell adhesion function.
In colorectal cancer, Kojima et al52 and Horst et al53 reported
a signiﬁcant correlation of increased CD133 expression and poor
clinical outcome. In contrast, in a study on non-small-cell lung
cancer, CD133 expression was not a prognostic factor for
survival.54 Consistent with the latter study, we found no
signiﬁcant impact of CD133 on survival in our series of
ampullary cancer patients.
In summary, we have provided evidence that in ampullary
carcinoma, loss of expression of EpCAM, but not of CD44,
CD133 or CD166, is linked to poor survival.
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